Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

April 14, 2022

Allogene Therapeutics, Inc.

740 Newpark Blvd., Suite 100
South San Francisco, CA 94080

(650) 890-6000

www.allogene.com

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the virtual unveiling of its manufacturing facility, Cell Forge 1 ("CF1"), located in South San Francisco, California.

CF1 includes modular production suites, which are flexible and adaptable for growth. It also includes space for quality control and testing, an environmental testing lab, and an advanced data system infrastructure, as well as administrative and warehouse space.

"In designing Cell Forge 1 we sought to prioritize adaptability, sustainability, and collaboration," said Ben Beneski, Vice President and CF1 Site Head at Allogene. "We expect the facility to enhance innovation across all facets of our business, including our ability to support the manufacture of AlloCAR T™ products on-demand, more reliably, and at greater scale to more patients. We are grateful to everyone, both at Allogene and in the community, who brought this vision to reality."".

"Cell Forge 1 is a critical piece of our strategy for revolutionizing CAR T cancer therapy. As we prepare for our first pivotal trial with ALLO-501A for the treatment of relapsed/refractory non-Hodgkin lymphoma, we look forward to using the capabilities of this state-of-the-art facility to meet product demand while maintaining important quality controls," said Alison Moore, Ph.D., Chief Technical Officer of Allogene. "We believe this is an ideal time to bring the facility online. Cell Forge 1 is designed to support clinical trial and potential commercial production and worldwide distribution of allogeneic CAR T cell products for blood cancers and solid tumors."

About Allogene

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer. AlloCAR T™ is a fully human T cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses of results of operations, and other statements that are not based on historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, the risks that the Company may be unable to progress AlloCAR T™ trials, including without limitation in Allogene’s filings with the SEC, or current expectations concerning, among other things: the timing and ability to obtain agreement with the U.S. Food and Drug Administration on the development plan for ALLO-501A; the timing and ability to manufacture AlloCAR T™ products; the timing and ability to obtain clearance from the U.S. Food and Drug Administration for additional clinical trials, including the ULTIMA trial; the ability of the Company to obtain regulatory approval to commercialize AlloCAR T™ products; the ability of the Company to obtain adequate reimbursement for AlloCAR T™ products; the ability to maintain insurance coverage and adequate reimbursement levels for AlloCAR T™ products; the timing and ability to enter into agreements with contract manufacturers; and the ability to obtain financing on acceptable terms. The Company's actual results and performance could differ materially from those expressed in, or implied by, these forward-looking statements. The forward-looking statements in this press release are based on current expectations and speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or otherwise, after the date of this press release. Any forward-looking statements that are made in this press release speak only as of the date of this press release.